San Francisco, CA (September 20, 2016) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced Dr. Richard Chin, President and CEO, will be presenting at the Ladenburg Thalmann Healthcare Conference in New York City on Tuesday, September 27, 2016 at 11:00 AM EDT. The conference is being held at the Sofitel Hotel.
An archived version of the webcast and presentation will be available for 30 days on the Company’s website: http://kindredbio.com/investor-relations/events.
About Kindred Biosciences, Inc.
Kindred Biosciences is a development-stage biopharmaceutical company focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The Company’s strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for dogs, cats and horses. The Company has a deep pipeline of novel drugs and biologics in development across many therapeutic classes.